FS-1502, an anti-HER2 ADC, in Patients with HER2-Expressing Advanced Solid Tumors: A Phase 1a Dose-Escalation Study

被引：2
|
作者：
Li, Qiao
Wang, Xian
Cheng, Ying
Liu, Yunjiang
Chang, Jianhua
Wang, Zhuo
Wu, Chunjiao
Wang, Mingxia
Hui, Ai-Min
Wu, Zhuli
Jin, Yongli
Huang, Xin
Zhong, Liping
Diao, Lei
Zhao, Han
Xu, Binghe
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P4-01-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-01-07
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
    Meric-Bernstam, Funda
    Calvo, Emiliano
    Lee, Keun Seok
    Moreno, Victor
    Park, Yeon Hee
    Rha, Sun Young
    Chalasani, Pavani
    Zhong, Wei
    Zhou, Li
    Pirie-Shepherd, Steven
    Leung, Abraham C. F.
    Curigliano, Giuseppe
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (10) : 1191 - 1203
  • [2] HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial
    Li, Qiao
    Cheng, Ying
    Tong, Zhongsheng
    Liu, Yunjiang
    Wang, Xian
    Yan, Min
    Chang, Jianhua
    Wang, Shusen
    Du, Caiwen
    Li, Liang
    Wu, Chunjiao
    Wang, Mingxia
    Wang, Zhuo
    Wu, Zhuli
    Wang, Xingli
    Jin, Yongli
    Diao, Lei
    Sun, Yi
    Zhang, Yongjiao
    Hui, Ai-Min
    Xu, Binghe
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [3] Phase 1 study of ZW25, a bispecific anti-HER2 antibody, in patients with advanced HER2-expressing cancers.
    Hausman, Diana Felice
    Hamilton, Erika Paige
    Beeram, Muralidhar
    Thimmarayappa, Jamuna
    Ng, Gordon
    Meric-Bernstam, Funda
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [4] POPULATION PHARM ACOKINETICS OF FS-1502, AN HER2 ANTIBODY-DRUG CONJUGATE (ADC), IN PATIENTS WITH HER2 EXPRESSED ADVANCED MALIGNANT SOLID TUMORS.
    Sun, Y.
    Li, C.
    Diao, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S96 - S96
  • [5] Phase I study of GQ1005, a new generation HER2-ADC, in patients with HER2-expressing and HER2 mutated advanced solid tumors
    Zhou, Caicun
    Yang, Bo
    Deng, Ting
    Wang, Biyun
    Zhang, Jian
    Sun, Yuping
    Wang, Linlin
    Yang, Hongwei
    Wang, Jingfen
    Li, Wei
    Song, Qi
    Yang, Yuchong
    CANCER RESEARCH, 2024, 84 (07)
  • [6] Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
    Banerji, Udai
    van Herpen, Carla M. L.
    Saura, Cristina
    Thistiethwaite, Fiona
    Lord, Simon
    Moreno, Victor
    Macpherson, Iain R.
    Boni, Valentina
    Rolfo, Christian
    de Vries, Elisabeth G. E.
    Rottey, Sylvie
    Geenen, Jilt
    Eskens, Ferry
    Gil-Martin, Marta
    Mommers, Ellen C.
    Koper, Norbert P.
    Aftimos, Philippe
    LANCET ONCOLOGY, 2019, 20 (08): : 1124 - 1135
  • [7] First-in-human, phase I dose escalation and expansion study of anti-HER2 ADC MRG002 in patients with HER2 positive solid tumors
    Guo, Y.
    Xue, J.
    Peng, W.
    Xue, L.
    Ge, X.
    Zhao, W.
    Tang, W.
    Nian, W.
    Li, Q.
    Zhang, S.
    Sun, J.
    Li, M.
    Hausheer, F.
    Hu, C.
    Li, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S480 - S481
  • [8] Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
    Meric-Bernstam, Funda
    Beeram, Muralidhar
    Hamilton, Erika
    Oh, Do-Youn
    Hanna, Diana L.
    Kang, Yoon-Koo
    Elimova, Elena
    Chaves, Jorge
    Goodwin, Rachel
    Lee, Jeeyun
    Nabell, Lisle
    Rha, Sun Young
    Mayordomo, Jose
    El-Khoueiry, Anthony
    Pant, Shubham
    Raghav, Kanwal
    Kim, Jin Won
    Patnaik, Amita
    Gray, Todd
    Davies, Rupert
    Ozog, Mark A.
    Woolery, Joseph
    Lee, Keun-Wook
    LANCET ONCOLOGY, 2022, 23 (12): : 1558 - 1570
  • [9] Preliminary results of a phase I, first-in-human, dose escalation study of IMM2902 in patients with HER2-expressing advanced solid tumors
    Meng, Yanchun
    Zhang, Jian
    Zhao, Chuanhua
    Cheng, Ying
    Zhu, Liming
    Song, Zhengbo
    Xu, Nong
    Wang, Zhen
    Wang, Yanping
    Du, Yiqun
    Jing, Deqiang
    Chen, Dinglu
    Qu, Qiaofeng
    Zhao, Xiwen
    Li, Wei
    Lu, Qiying
    Tian, Wenzhi
    Xu, Jianming
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers
    Beeram, M.
    Hamilton, E.
    Murphy, M. Blum
    Hausman, D.
    Infante, J. R.
    Korn, R.
    Patnaik, A.
    Piha-Paul, S. A.
    Rasco, D.
    Rowse, G.
    Thimmarayappa, J.
    Tolcher, A.
    Meric-Bernstam, F.
    ANNALS OF ONCOLOGY, 2017, 28
12345